v3.26.1
Other Operating Income and Expenses
 12 Months Ended
Mar. 31, 2026
Analysis of income and expense [abstract]  
Other Operating Income and Expenses Other Operating Income and Expenses
JPY (millions)
For the Year Ended March 31
202420252026
Other operating income:
Change in fair value of financial assets and liabilities associated with contingent consideration arrangements (Note 26)¥— ¥2,390 ¥— 
Gain on sales of property, plant and equipment and investment property144 363 165 
Gain on divestment of business to Teva Takeda Yakuhin588 4,117 — 
Gain on divestment of business and subsidiaries (Note 18)7,243 6,081 18,265 
Other11,404 13,262 6,318 
Total¥19,379 ¥26,212 ¥24,747 
Other operating expenses:
Donations and contributions¥7,009 ¥7,663 ¥6,866 
Restructuring expenses (Note 22)81,358 128,133 70,818 
Change in fair value of financial assets and liabilities associated with contingent consideration arrangements (Note 26)20,757 1,788 1,006 
Valuation reserve for pre-launch inventories (reversal)11,052 (7,313)50,984 
Impairment of assets held for sale (Note 18)1,685 6,812 1,363 
Provisions for legal proceedings related to AMITIZA (Note 31)— — 403,478 
Other84,666 69,650 24,466 
Total¥206,527 ¥206,733 ¥558,979 
For the year ended March 31, 2024, ”Other” in other operating expenses includes JPY 45,212 million of legal provision for certain legal proceeding, comprising JPY 26,405 million of additional losses recorded for the supply agreement litigation with AbbVie, Inc. ("AbbVie").
For the year ended March 31, 2025, ”Other” in other operating expenses includes JPY 27,004 million of post-trial access costs related to TAK-611 and TAK-609.